InnoCare Pharma Limited (HKG:9969)
15.64
-0.19 (-1.20%)
Apr 17, 2026, 1:25 PM HKT
InnoCare Pharma Employees
InnoCare Pharma had 1,176 employees as of June 30, 2025. The number of employees increased by 87 or 7.99% compared to the previous year.
Employees
1,176
Change
87
Growth
7.99%
Revenue / Employee
2.25M HKD
Profits / Employee
607.95K HKD
Market Cap
32.23B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2025 | 1,176 | 87 | 7.99% |
| Dec 31, 2023 | 1,089 | 150 | 15.97% |
| Dec 31, 2022 | 939 | 218 | 30.24% |
| Dec 31, 2021 | 721 | 269 | 59.51% |
| Dec 31, 2020 | 452 | 238 | 111.21% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Genscript Biotech | 6,165 |
| Shanghai Henlius Biotech | 3,762 |
| Shanghai Junshi Biosciences | 2,903 |
| Zai Lab | 1,784 |
| Keymed Biosciences | 1,625 |
| Biocytogen Pharmaceuticals (Beijing) | 1,306 |
| Ascentage Pharma Group International | 767 |
| Duality Biotherapeutics | 231 |
InnoCare Pharma News
- 22 days ago - InnoCare Releases 2025 Results and Business Highlights, Achieving First Annual Profit - GlobeNewsWire
- 4 weeks ago - InnoCare Announces First Healthy Volunteer Dosed in Clinical Trial of Novel VAV1 Degrader ICP-538 in China - GlobeNewsWire
- 7 weeks ago - InnoCare Announces Key Developments of Critical Clinical Studies - GlobeNewsWire
- 2 months ago - InnoCare Announces First Patient Dosed in the Phase II/III Clinical Trial of Novel TYK2 Inhibitor Soficitinib for Chronic Spontaneous Urticaria in China - GlobeNewsWire
- 4 months ago - InnoCare Announces Approval of Phase II/III Clinical Trial of Novel TYK2 Inhibitor Soficitinib for Chronic Spontaneous Urticaria in China - GlobeNewsWire
- 4 months ago - Over 20 Studies of InnoCare's Orelabrutinib Presented at the 67th Annual Meeting of the American Society of Hematology (ASH) - GlobeNewsWire
- 5 months ago - InnoCare Announces First Patient Dosed in the Global Phase II Clinical Trial of TYK2 Inhibitor Soficitinib for Treatment of Prurigo Nodularis - GlobeNewsWire